Baseline disease characteristics
| Baseline characteristics . | Population (N = 39) . |
|---|---|
| Disease stage IV, n (%) | 30/37 (81.1) |
| Transformed FL, n (%) | 8/38 (21.5) |
| International Prognostic Index score, median (range) (n = 36) | 3 (0-4) |
| Prior DLBCL treatments, mean (min-max) | 3.3 (1-6) |
| CAR T, n (%) | 2 (5.1) |
| Bispecific antibodies, n (%) | 5 (12.8) |
| Interval between prior treatment and study treatment | |
| ≤1 mo | 11 (28.2) |
| >1 mo and ≤ 3 mo | 17 (43.6) |
| > 3 mo | 11 (28.2) |
| Cell of origin, n (%) | |
| GCB | 24/33 (72.7) |
| ABC | 7/33 (21.2) |
| MYC+BCL2 DE-DLBCL, n (%) | 10/18 (55.5) |
| MYC translocation, n (%) | 1/30 (3.3) |
| BCL2 translocation, n (%) | 9/30 (30.0) |
| Baseline characteristics . | Population (N = 39) . |
|---|---|
| Disease stage IV, n (%) | 30/37 (81.1) |
| Transformed FL, n (%) | 8/38 (21.5) |
| International Prognostic Index score, median (range) (n = 36) | 3 (0-4) |
| Prior DLBCL treatments, mean (min-max) | 3.3 (1-6) |
| CAR T, n (%) | 2 (5.1) |
| Bispecific antibodies, n (%) | 5 (12.8) |
| Interval between prior treatment and study treatment | |
| ≤1 mo | 11 (28.2) |
| >1 mo and ≤ 3 mo | 17 (43.6) |
| > 3 mo | 11 (28.2) |
| Cell of origin, n (%) | |
| GCB | 24/33 (72.7) |
| ABC | 7/33 (21.2) |
| MYC+BCL2 DE-DLBCL, n (%) | 10/18 (55.5) |
| MYC translocation, n (%) | 1/30 (3.3) |
| BCL2 translocation, n (%) | 9/30 (30.0) |